Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice.

Buchler T, Kiss I, Hornova J, Fiala O, Wiesnerova M, Svoboda M, Silar J, Kopeckova K, Poprach A, Finek J, Petruzelka L, Melichar B.

Target Oncol. 2020 Feb 12. doi: 10.1007/s11523-020-00705-1. [Epub ahead of print]

PMID:
32052341
2.

MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer.

Vychytilova-Faltejskova P, Svobodova Kovarikova A, Grolich T, Prochazka V, Slaba K, Machackova T, Halamkova J, Svoboda M, Kala Z, Kiss I, Slaby O.

Int J Mol Sci. 2019 Sep 10;20(18). pii: E4460. doi: 10.3390/ijms20184460.

3.

Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.

Vyskocil J, Tucek S, Kiss I, Fedorova L, Nevrlka J, Zdrazilova-Dubska L.

Int Immunopharmacol. 2019 Sep;74:105728. doi: 10.1016/j.intimp.2019.105728. Epub 2019 Jul 6.

PMID:
31288153
4.

Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database.

Poprach A, Rumanova K, Lakomý R, Chloupková R, Stanik M, Pokrivcak T, Kiss I, Slaby O, Studentova H, Melichar B, Juracek J, Fiala O, Kopecky J, Kopeckova K, Zemanova M, Buchler T.

Urol Oncol. 2019 Apr;37(4):294.e1-294.e8. doi: 10.1016/j.urolonc.2018.12.017. Epub 2019 Jan 23.

PMID:
30683455
5.

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.

Buchler T, Chloupkova R, Poprach A, Fiala O, Kiss I, Kopeckova K, Dusek L, Veskrnova V, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Melichar B.

Cancer Manag Res. 2018 Dec 28;11:359-368. doi: 10.2147/CMAR.S183093. eCollection 2019.

6.

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.

Fiala O, Veskrnova V, Chloupkova R, Poprach A, Kiss I, Kopeckova K, Dusek L, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Boubliková L, Dvorak J, Melichar B, Buchler T.

Target Oncol. 2018 Dec;13(6):735-743. doi: 10.1007/s11523-018-0597-7.

PMID:
30353488
7.

Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.

Karasek P, Gablo N, Hlavsa J, Kiss I, Vychytilova-Faltejskova P, Hermanova M, Kala Z, Slaby O, Prochazka V.

Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):321-327. doi: 10.21873/cgp.20090.

8.

Circulating PIWI-Interacting RNAs piR-5937 and piR-28876 Are Promising Diagnostic Biomarkers of Colon Cancer.

Vychytilova-Faltejskova P, Stitkovcova K, Radova L, Sachlova M, Kosarova Z, Slaba K, Kala Z, Svoboda M, Kiss I, Vyzula R, Cho WC, Slaby O.

Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1019-1028. doi: 10.1158/1055-9965.EPI-18-0318. Epub 2018 Jul 5.

9.

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.

Poprach A, Fiala O, Chloupkova R, Melichar B, Lakomy R, Petrakova K, Zemanova M, Kopeckova K, Slaby O, Studentova H, Kopecký J, Kiss I, Finek J, Dusek L, Buchler T.

Anticancer Res. 2018 Jan;38(1):449-456.

PMID:
29277808
10.

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.

Lakomy R, Poprach A, Bortlicek Z, Melichar B, Chloupkova R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Juracek J, Fiala O, Kopecky J, Finek J, Dusek L, Hejduk K, Buchler T.

BMC Cancer. 2017 Dec 21;17(1):880. doi: 10.1186/s12885-017-3901-5.

11.

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9.

Vychytilova-Faltejskova P, Merhautova J, Machackova T, Gutierrez-Garcia I, Garcia-Solano J, Radova L, Brchnelova D, Slaba K, Svoboda M, Halamkova J, Demlova R, Kiss I, Vyzula R, Conesa-Zamora P, Slaby O.

Oncogenesis. 2017 Dec 4;6(11):399. doi: 10.1038/s41389-017-0006-6.

12.

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management.

Krakorova DA, Kubackova K, Dusek L, Tomas T, Janicek P, Tucek S, Prausova J, Kiss I, Zambo I.

Pathol Oncol Res. 2018 Jul;24(3):623-630. doi: 10.1007/s12253-017-0291-6. Epub 2017 Aug 12.

PMID:
28803261
13.

Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.

Buchler T, Poprach A, Bortlicek Z, Lakomy R, Chloupková R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Hornova J, Fiala O, Kopecky J, Finek J, Dusek L, Melichar B; Czech Metastatic Renal Cancer Cooperative Group.

Clin Genitourin Cancer. 2017 Dec;15(6):e1047-e1053. doi: 10.1016/j.clgc.2017.06.006. Epub 2017 Jun 29.

PMID:
28720439
14.

Aberrant methylation of tumour suppressor genes WT1, GATA5 and PAX5 in hepatocellular carcinoma.

Mžik M, Chmelařová M, John S, Laco J, Slabý O, Kiss I, Bohovicová L, Palička V, Nekvindová J.

Clin Chem Lab Med. 2016 Dec 1;54(12):1971-1980. doi: 10.1515/cclm-2015-1198.

PMID:
27171388
15.

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.

Kopeckova K, Buchler T, Bortlicek Z, Hejduk K, Chloupkova R, Melichar B, Pokorna P, Tomasek J, Linke Z, Petruzelka L, Kiss I, Prausova J.

Target Oncol. 2017 Feb;12(1):89-95. doi: 10.1007/s11523-016-0458-1.

PMID:
27638381
16.

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.

Kiss I, Mlcochova J, Bortlicek Z, Poprach A, Drabek J, Vychytilova-Faltejskova P, Svoboda M, Buchler T, Batko S, Ryska A, Hajduch M, Slaby O.

Anticancer Res. 2016 Sep;36(9):4955-9.

PMID:
27630355
17.

Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.

Poprach A, Lakomy R, Bortlicek Z, Melichar B, Pavlik T, Slaby O, Vyzula R, Svoboda M, Kiss I, Studentova H, Zemanova M, Fiala O, Kubackova K, Dusek L, Hornova J, Buchler T; Czech Renal Cell Cancer Cooperative Group.

Drugs Aging. 2016 Sep;33(9):655-63. doi: 10.1007/s40266-016-0390-1.

PMID:
27541802
18.

Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer.

Vychytilova-Faltejskova P, Radova L, Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V, Kala Z, Svoboda M, Kiss I, Vyzula R, Slaby O.

Carcinogenesis. 2016 Oct;37(10):941-950. doi: 10.1093/carcin/bgw078. Epub 2016 Aug 1.

PMID:
27485599
19.

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.

Benson AB 3rd, Kiss I, Bridgewater J, Eskens FA, Sasse C, Vossen S, Chen J, Van Sant C, Ball HA, Keating A, Krivoshik A.

Clin Cancer Res. 2016 Oct 15;22(20):5058-5067. Epub 2016 Jul 11.

20.

Genome-wide microRNA Expression Profiling in Primary Tumors and Matched Liver Metastasis of Patients with Colorectal Cancer.

Vychytilova-Faltejskova P, Pesta M, Radova L, Liska V, Daum O, Kala Z, Svoboda M, Kiss I, Slaby O.

Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):311-6.

PMID:
27365381

Supplemental Content

Loading ...
Support Center